Compare AAT & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAT | OGN |
|---|---|---|
| Founded | 1967 | 1923 |
| Country | United States | United States |
| Employees | 208 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2010 | 2020 |
| Metric | AAT | OGN |
|---|---|---|
| Price | $22.77 | $13.72 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $19.50 | $11.40 |
| AVG Volume (30 Days) | 388.5K | ★ 2.6M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.65% | 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.08 | ★ 0.95 |
| Revenue | $436,204,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $4.33 | $0.45 |
| Revenue Next Year | $0.22 | $1.67 |
| P/E Ratio | $287.00 | ★ $14.44 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.72 | $5.69 |
| 52 Week High | $25.97 | $13.72 |
| Indicator | AAT | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 75.31 |
| Support Level | $18.23 | $13.46 |
| Resistance Level | $25.76 | N/A |
| Average True Range (ATR) | 0.52 | 0.04 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 23.43 | 97.50 |
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.